Clinical Trial Update: Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating tezepelumab for eosinophilic granulomatosis with polyangiitis (EGPA) to evaluate efficacy and mechanism of action.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Tezepelumab (tezepelumab)

Snippet

Sponsor: Imperial College London | Conditions: EGPA - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 | Status: ENROLLING_BY_INVITATION